Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence

Clinical Oncology

Volumn 22, Issue 5, 2010, Pages 347-355

  O'Rourke, N ^a   Macbeth, F ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

Concurrent chemoradiation; Guidelines; NSCLC; Sequential treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINDESINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; DRUG FATALITY; ESOPHAGITIS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MANAGED CARE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY;

EID: 77952708256     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.03.007     Document Type: Article

References (38)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-2002 analysis of EUROCARE-4 data. Lancet Oncol 2007, 8(9):784-796.
3. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favourable patients with RTOG stage III NSCLC: report of RTOG 83-11. J Clin Oncol 1990, 8:1543-1555.
4. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 1999, 52:137-148.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311:899-909. Non-small Cell Lung Cancer Collaborative Group.
6. Auperin A., Le Pechoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced NSCLC: a meta-analysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483.
7. Rowell N.P., O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004, 4. CD002140.
8. American Society of Clinical Oncology Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 2004, 22:330-353.
9. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
10. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410 (abstract). Proc Am Soc Oncol 2003, 22:621.
11. IASLC Workshop Combined modality therapy for unresectable non-small cell lung cancer. Lung Cancer 2003, 42:S47-S51.
12. Okawara G., Mackay J.A., Evans W.K., et al. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thor Oncol 2006, 1:377-393.
13. Schaake-Koning C., van den bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992, 326:524-530.
14. Australian National Health and Medical Research Council Clinical practice guideline for prevention, diagnosis and management of lung cancer 2004, Australian National Health and Medical Research Council.
15. Movsas B, Scott C, Curran W, et al. A quality-adjusted time without symptoms or toxicity (QTWiST) analysis of RTOG 9410. Proceedings of ASCO, 2001.
16. National Institute for Health and Clinical Excellence The diagnosis and treatment of lung cancer 2005, National Institute for Health and Clinical Excellence, London.
17. Scottish Intercollegiate Guidelines Network Management of patients with lung cancer, no 80 2005, Scottish Intercollegiate Guidelines Network.
18. ACCP Guidelines Treatment of non-small cell lung cancer stage IIIA and IIIB. Chest 2007, 132:243-276.
19. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: groupe Lyon-Saint-Etienne d'oncologie thoracique groupe francais de pneumocancerologie NPC 95-01. J Clin Oncol 2005, 23:5910-5917.
20. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer; a randomized study. Lung Cancer 2004, 46:87-98.
21. Reinfuss M., Skolyszewski J., Kowalska T., et al. Evaluation of efficacy of combined chemoradiotherapy in locoregional advanced, inoperable non-small cell lung cancer (clinical randomized trial). Nowotwory 2005, 55:200-206.
22. Belani C., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 2005, 23:5883-5891.
23. Dasgupta A., Dasgupta C., Basu S., et al. A prospective randomized study of radiotherapy, sequential chemoradiotherapy and concomitant chemoradiotherapy in unresectable non-small cell lung cancer. J Cancer Res Ther 2006, 2(2):47-51.
24. Huber R.M., Flentje M., Schmidt M., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage III non-small cell lung cancer: study CTRT99/97. J Clin Oncol 2006, 24(27):4397-4404.
25. Vokes E., Crawford J., Bogart J., et al. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 2005, 11:5045-5050.
26. Gouda Y.S., Kohail H.M., Eldeeb N.A., et al. Randomized study of concurrent carboplatin, paclitaxel and radiotherapy with or without induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Nat Cancer Inst 2006, 18(1):73-81.
27. Belderbos J., Uitterhoeve L., van Zandwijk N., et al. Randomised trial of sequential versus concurrent chemoradiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43(1):114-121.
28. Glynne-Jones R., Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation; a flawed paradigm?. J Clin Oncol 2007, 25(33):5281-5286.
29. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986, 70:163.
30. El Sharouni S.Y., Kal H.B., Batterman J.J. Accelerated regrowth of non-small cell lung tumours after induction chemotherapy. Br J Cancer 2003, 89(12):2184-2189.
31. O'Rourke N.P., Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol 2000, 12(3):141-144.
32. Petersen C., Eicheler W., Frommel A., et al. Proliferation and micomilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003, 79:469-477.
33. Belani C., Wang W., Johnson D.H., et al. Phase III study of ECOG: induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage III NSCLC. J Clin Oncol 2005, 23:3760-3767.
34. Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol 2008, 13:112-116.
35. Langer C.J., Moughan J., Movsas B., et al. Patterns of care survey in lung cancer: how well does current US practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer 2005, 48(1):93-102.
36. Kepka L., Casa F., Perin B., et al. Radiochemotherapy for lung cancer in developing countries. Clin Oncol 2009, 721(7):536-542.
37. Macbeth F., Abratt A., Cho K., et al. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol 2007, 82:123-131.
38. Hanna N., Neubauer M., Yiannoutsos C., et al. Phase III study of cisplatin, etoposide and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III NSCLC. J Clin Oncol 2008, 26(35):5755-5760.